用Janus激酶1抑制剂阿布昔替尼成功治疗重度甲扁平苔藓
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib.
作者信息
Luo Yingzhi, Wu Jian, Zhao Xingyun, Yang Ping, Qiu Yunmi, Wu Liming, Zhong Jianbo
机构信息
Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Department of Pathology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
出版信息
Clin Cosmet Investig Dermatol. 2025 May 2;18:1095-1100. doi: 10.2147/CCID.S520633. eCollection 2025.
Nail lichen planus (NLP) is a chronic inflammatory disease that presents a significant therapeutic challenge. It can progress rapidly, leading to impaired nail morphology and function. Currently, there is no established standard therapy due to limited efficacy or potential for significant adverse reactions. In this report, we present a case of very severe NLP successfully treated with the Janus kinase 1 (JAK1) inhibitor abrocitinib, with no associated discomfort.
甲扁平苔藓（NLP）是一种慢性炎症性疾病，带来了重大的治疗挑战。它可能迅速进展，导致指甲形态和功能受损。目前，由于疗效有限或存在显著不良反应的可能性，尚无既定的标准疗法。在本报告中，我们介绍了一例非常严重的NLP患者成功接受Janus激酶1（JAK1）抑制剂阿布昔替尼治疗，且无相关不适的病例。
Zotero 插件